GSK Moves Closer To Priority Review Voucher As US Panel Backs Malaria Drug Tafenoquine

 
• By Sue Sutter

GlaxoSmithKline's user fee date is July 22, four days before advisory committee review of 60 Degrees’ separate application for the compound.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers